Moreover, anti-α-TIGIT scFv expression and secretion interrupted the interaction between TIGIT and its ligand CD155, enhancing the infiltration and activation of CAR-T cells in the TME to achieve increased tumor regression in vivo [216]. The gene discussed is TIGIT; the disease is neoplasm.